A retrospective cohort study identifying the principal pathological features useful in the diagnosis of inclusion body myositis

BMJ Open

Volumn 4, Issue 4, 2014, Pages

  Brady, Stefen ^a   Squier, Waney ^b   Sewry, Caroline ^c,d   Hanna, Michael ^a   Hilton Jones, David ^e   Holton, Janice L ^f  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d ROBERT JONES AND AGNES HUNT ORTHOPAEDIC HOSPITAL   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN; BIOLOGICAL MARKER;

ADULT; ARTICLE; CELL VACUOLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INCLUSION BODY MYOSITIS; MALE; MYOPATHY; MYOSITIS; PROTEIN AGGREGATION; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; T LYMPHOCYTE; ALGORITHM; BIOPSY; CLINICAL TRIAL; ENGLAND; METABOLISM; MULTICENTER STUDY; PATHOLOGY;

ALGORITHMS; BIOMARKERS; BIOPSY; FEMALE; HUMANS; LONDON; MALE; MYOSITIS, INCLUSION BODY; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 84899544973     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004552     Document Type: Article

References (24)

1. Needham M, Corbett A, Day T, et al. Prevalence of sporadic inclusion body myositis and factors contributing to delayed diagnosis. J Clin Neurosci 2008;15:1350-3.
2. Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol 1995;38:705-13.
3. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 1984;16:193-208. (Pubitemid 14062666)
4. Mhiri C, Gherardi R. Inclusion body myositis in French patients. A clinicopathological evaluation. Neuropathol Appl Neurobiol 1990;16:333-44. (Pubitemid 20246016)
5. Villanova M, Kawai M, Lübke U, et al. Rimmed vacuoles of inclusion body myositis and oculopharyngeal muscular dystrophy contain amyloid precursor protein and lysosomal markers. Brain Res 1993;603:343-7. (Pubitemid 23069237)
6. Van der Meulen MF, Hoogendijk JE, Moons KG, et al. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord 2001;11:447-51. (Pubitemid 32510004)
7. Ferrer I, Olivé M. Molecular pathology of myofibrillar myopathies. Expert Rev Mol Med 2008;10:e25.
8. Amato AA, Gronseth GS, Jackson CE, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol 1996;40:581-6. (Pubitemid 26357882)
9. Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 2008;70:418-24.
10. Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain 2011;134:3176-84.
11. Brady S, Squier W, Hilton-Jones D. Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. J Neurol Neurosurg Psychiatry 2013;84:1240-6.
12. Greenberg SA. Theories of the pathogenesis of inclusion body myositis. Curr Rheumatol Rep 2010;12:221-8.
13. Sherriff FE, Joachim CL, Squier MV, et al . Ubiquitinated inclusions in inclusion-body myositis patients are immunoreactive for cathepsin D but not β-amyloid. Neurosci Lett 1995;194:37-40.
14. Greenberg SA. How citation distortions create unfounded authority: analysis of a citation network. BMJ 2009;339:b2680.
15. Needham M, Mastaglia FL. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol 2007;6:620-31. (Pubitemid 46921056)
16. Benveniste O, Hilton-Jones D. International workshop on inclusion body myositis held at the Institute of Myology, Paris, on 29 May 2009. Neuromuscul Disord 2010;20:414-21.
17. Wedderburn LR, Varsani H, Li CKC, et al. International consensus on a proposed score system for muscle biopsy evaluation in patients with juvenile dermatomyositis: a tool for potential use in clinical trials. Arthritis Rheum 2007;57:1192-201. (Pubitemid 47585465)
18. Nogalska A, Terracciano C, D'Agostino C, et al. p62/SQSTM1 is overexpressed and prominently accumulated in inclusions of sporadic inclusion-body myositis muscle fibers, and can help differentiating it from polymyositis and dermatomyositis. Acta Neuropathol 2009;118:407-13.
19. Weihl CC, Temiz P, Miller SE, et al. TDP-43 accumulation in inclusion body myopathy muscle suggests a common pathogenic mechanism with frontotemporal dementia. J Neurol Neurosurg Psychiatry 2008;79:1186-9.
20. Banwell BL, Engel AG. Alpha B-crystallin immunolocalization yields new insights into inclusion body myositis. Neurology 2000;54:1033-41. (Pubitemid 30151842)
21. Dubourg O, Wanschitz J, Maisonobe T, et al . Diagnostic value of markers of muscle degeneration in sporadic inclusion body myositis. Acta Myol 2011;30:103-8.
22. Hiniker A, Daniels BH, Lee HS, et al . Comparative utility of LC3, p62 and TDP-43 immunohistochemistry in differentiation of inclusion body myositis from polymyositis and related inflammatory myopathies. Acta Neuropathol Commun 2013; 1:29.
23. D'Agostino C, Nogalska A, Engel WK, et al. In sporadic inclusion-body myositis muscle fibres TDP-43-positive inclusions are less frequent and robust than p62-inclusions, and are not associated with paired helical filaments. Neuropathol Appl Neurobiol 2010; http://www.ncbi.nlm.nih.gov/pubmed/20626631
24. Momma K, Noguchi S, Malicdan MCV, et al. Rimmed vacuoles in Becker muscular dystrophy have similar features with inclusion myopathies. PLoS ONE 2012;7:e52002.